Clinical trials: sponsored by Zhejiang Cancer Hospital
Non-small Cell Lung Cancer
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Analysis of driver gene variation in early stage non-small cell lung cancer
- Trial name
- NCT04266691
- Testing
- nonIntervention
- Volunteers
- 237 people
- Sponsor
- Zhejiang Cancer Hospital
Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer
Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test
This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received…
- Trial name
- CMTNCMB (NCT04264468)
- Testing
- neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Non-Small-Cell Lung
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligo-metastatic non-small cell lung cancer…
- Trial name
- NCT04255836
- Testing
- Durvalumab, the first line chemotherapy for metastatic NSCLC, stereotactic body radiotherapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Adenocarcinoma
Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study
Preclinical studies have shown that Toripalimab and Nivolumab and Pembrolizumab have similar safety but better in vivo efficacy than target monoclonal antibody candidates with different sequence characteristics.In addition…
- Trial name
- NCT04190745
- Testing
- Toripalimab+Apatinib mesylate, paclitaxel
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Biliary Tract Tumors
Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen
This is an open, single-arm, single-center, prospective phase II clinical study to evaluate the efficacy and safety of first-line tripletrumab combined with GEMOX chemotherapy in patients with advanced biliary tract tumors.
- Trial name
- NCT04191343
- Testing
- Toripalimab injection combined with GEMOX
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Cancer Limited Stage
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.
- Trial name
- NCT04189094
- Testing
- Sintilimab, Etoposide, Cisplatin
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Unresectable Stage III NSCLC
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%.
- Trial name
- R-helper (NCT04161352)
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer
CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
This was a prospective, single arm, phase 2 trial. Adult Patients with histologically confirmed locally advanced cervical cancer were enrolled to receive the treatment of concurrent chemoradiotherapy combined with Endostar.
- Trial name
- NCT04121975
- Testing
- Radiotherapy, Endostar, Cisplatin
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Zhejiang Cancer Hospital
Lymph Node, Breastcancer
CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer
To establish a predicting system on axillary lymph node metastasis based on peripheral blood CK19mRNA and contrast-enhanced ultrasound.
- Trial name
- CK-CEUS (NCT02992067)
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy
The luminal subtype of breast cancer means hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+HER2-), which counted 60%-70% of breast cancer but achieve low pathologic complete response (pCR) rate…
- Trial name
- RSBNAT (NCT03638648)
- Testing
- Capecitabine
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
- Trial name
- NCT03940001
- Testing
- Sintilimab, carboplatin/paclitaxel, Radiation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Hepatocellular
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
- Trial name
- NCT04066543
- Testing
- TACE, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Peripheral T Cell Lymphoma
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma
- Trial name
- NCT04061772
- Testing
- Bortezomib, Etoposide, Cyclophosphamide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Neoplasm, Breast
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel and Carboplatin versus placebo and trastuzumab plus docetaxel and…
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases
- Trial name
- NCT03756064
- Testing
- Pyrotinib, Trastuzumab, Docetaxel
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Renal Cell Carcinoma
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
The investigators reported previously that epigenetic activation of organic cation transporter (OCT2) by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts.
- Trial name
- NCT04049344
- Testing
- Decitabine; Oxaliplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Adenocarcinoma
Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma
This study evaluates the addition of adjuvant chemoradiotherapy to adjuvant chemotherapy in the treatment of locally advanced proximal gastric adenocarcinoma after standard D2 radical resection.
- Trial name
- NCT03973008
- Testing
- Adjuvant Chemoradiotherapy, Adjuvant Chemotherapy
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Zhejiang Cancer Hospital
Lymph Node Metastases, Breast Cancer
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer
In the previous study, the investigator established a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement).
- Conditions
- Lymph Node Metastases, Breast Cancer, Predictive Cancer Model
- Trial name
- NCT03280134
- Testing
- axillary lymph node dissection (ALND)
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Neoplasms, Neoadjuvant Therapy
Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer
Application of circulating tumor DNA detection in diagnosis and treatment of locally advanced rectal cancer. First, to explore the feasibility of ctDNA as a detection index for rectal cancer.
- Conditions
- Rectal Neoplasms, Neoadjuvant Therapy, Circulating Tumor DNA
- Trial name
- NCT03615170
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer
This research study is studying endostar in combination with chemotherapy as a possible treatment for HER-2 negative advanced breast cancer.
- Trial name
- NCT03907098
- Testing
- Endostar, Chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.
- Trial name
- NCT03876587
- Testing
- Pyrotinib Maleate combine with Docetaxel
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Zhejiang Cancer Hospital